Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | NR3C2 | P08235 | 7/20 | 0.43 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29397815 | 1.00 | NPC1 (0.45) | NPC1CYP11B1CYP11B2NR3C2MMP12 | |
| Hydrochloric Acid SCHEMBL30048713 | 0.98 | NPC1 (0.44) | NPC1CYP11B1CYP11B2NR3C2MMP12 | |
| SCHEMBL30987426 | 0.83 | NPC1 (0.43) | NPC1SMN1; SMN2CYP1A2RIPK1 | |
| SCHEMBL7320965 | 0.83 | NPC1 (0.43) | NPC1SMN1; SMN2CYP1A2RIPK1 | |
| Hydrochloric Acid SCHEMBL30987420 | 0.81 | NPC1 (0.42) | NPC1SMN1; SMN2KMT2ACYP1A2RIPK1 | |
| SCHEMBL9755357 | 0.77 | CRBN (0.39) | NPC1CYP11B1CYP11B2SMN1; SMN2CYP1A2 | |
| Bicarbonate SCHEMBL30250613 | 0.77 | NPC1 (0.42) | NPC1NR3C2SMN1; SMN2KMT2ACYP1A2 | |
| SCHEMBL14279297 | 0.76 | CYP1A2 (0.42) | SMN1; SMN2KMT2ANPSR1CYP1A2 | |
| SCHEMBL19228635 | 0.73 | NPC1 (0.48) | NPC1SMN1; SMN2KMT2ACYP1A2RIPK1 | |
| SCHEMBL2840325 | 0.73 | NPC1 (0.55) | NPC1SMN1; SMN2ALDH1A1CYP1A2RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1475 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3768675-B1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORP (KR) | 2026-04-01 | — | — | EP | claimed |
| US-12577248-B2 | Substituted [1,2,4]triazolo[1,5-a]pyrazines as spleen tyrosine kinase inhibitors | NANJING RUIJIE PHARMA CO., LTD. (CN) | 2026-03-17 | — | — | US | claimed |
| EP-4126855-B1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN LA ROCHE (CH) | 2024-04-24 | — | — | EP | claimed |
| US-11780830-B2 | Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2023-10-10 | — | — | US | claimed |
| EP-3458452-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION | BUGWORKS RES INC (US) | 2023-08-30 | — | — | EP | claimed |
| EP-3717490-B1 | ANTI-BACTERIAL HETEROCYCLIC COMPOUNDS AND THEIR SYNTHESIS | BUGWORKS RES INC (US) | 2023-05-24 | — | — | EP | claimed |
| EP-4126855-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | F. Hoffmann-La Roche AG (CH) | 2023-02-08 | — | — | EP | claimed |
| EP-3774790-B1 | OXAZOLIDINONE ANTIBIOTIC COMPOUNDS AND PROCESS OF PREPARATION | BUGWORKS RES INC (US) | 2023-01-25 | — | — | EP | claimed |
| EP-3634968-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION THEREOF | BUGWORKS RES INC (US) | 2023-01-25 | — | — | EP | claimed |
| US-11492335-B2 | Aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2022-11-08 | — | — | US | claimed |
| WO-2009151683-A2 | QUINOLINONE FARNESYL TRANSFERASE INHIBITORS FOR THE TREATMENT OF SYNUCLEINOPATHIES AND OTHER INDICATIONS | LINK MEDICINE CORPORATION (US) | 2009-12-17 | — | — | WO | claimed |
| EP-2007377-A2 | ANTIBACTERIAL AGENTS | Glaxo Group Limited (GB) | 2008-12-31 | — | — | EP | claimed |
| WO-2007118130-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2007-10-18 | — | — | WO | claimed |
| EP-1021190-B1 | Amid derivatives as growth hormone release promotors | KAKEN PHARMA CO LTD (JP) | 2006-11-08 | — | — | EP | claimed |
| EP-1560488-A4 | ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM CORP (US) | 2006-08-02 | — | — | EP | claimed |
| EP-1560488-A2 | ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-10 | — | — | EP | claimed |
| WO-2004041210-A2 | ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-05-21 | — | — | WO | claimed |
| EP-0357675-A4 | PYRIDOOXAZINONE-PYRIDONE COMPOUNDS, CARDIOTONIC COMPOSITIONS INCLUDING THE SAME, AND THEIR USES | — | 1992-01-15 | — | — | EP | claimed |
| EP-0357675-A1 | PYRIDOOXAZINONE-PYRIDONE COMPOUNDS, CARDIOTONIC COMPOSITIONS INCLUDING THE SAME, AND THEIR USES | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1990-03-14 | — | — | EP | claimed |
| WO-1988008705-A1 | PYRIDOOXAZINONE-PYRIDONE COMPOUNDS, CARDIOTONIC COMPOSITIONS INCLUDING THE SAME, AND THEIR USES | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1988-11-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11492335-B2 | Aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same | CYP7A1, NAT1, NCOA1 | NPC1 21/4885CYP11B1 221/4885CYP11B2 445/4885 |
| US-11780830-B2 | Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same | SLC10A1, VAT1, LIPC | NPC1 20/4885CYP11B1 449/4885CYP11B2 885/4885 |
| US-12577248-B2 | Substituted [1,2,4]triazolo[1,5-a]pyrazines as spleen tyrosine kinase inhibitors | SYK, BTK, TYRO3 | NPC1 3649/4885CYP11B1 2581/4885CYP11B2 2643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.